课题基金 / 基金详情

EVALUATION OF GI147211 ADMINISTRATION DAILY BY INJECTION ON FIVE CONSECUTIVE DAYS

EVALUATION OF GI147211 ADMINISTRATION DAILY BY INJECTION ON FIVE CONSECUTIVE DAYS
连续五天每日注射的 GI147211 给药评价
批准号：
6244971
负责人：
STEPHEN BERNARD
金额：
$1.34万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-06 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244971
关键词：
antineoplastics breast neoplasms clinical research clinical trials colorectal neoplasms drug administration rate /duration drug administration routes drug screening /evaluation drug tolerance human subject human therapy evaluation lung neoplasms neoplasm /cancer chemotherapy pathologic process prostate neoplasms

项目摘要

项目成果

STEPHEN BERNARD的其他基金

相似基金

相关文献

中文摘要
翻译
结直肠癌是美国最常见的癌症之一， 其次是女性乳腺癌，第三是前列腺癌和肺癌。 男性癌症 最近的预测表明，1994年， 结直肠癌病例（107，000例结肠癌，42，000例直肠癌）将在 确诊后，56，000名患者将死于该病。 目标是 以确定GI 147211的应答率。 为了确定时间， 疾病进展，并评估安全性和耐受性， 每日注射。
英文摘要
Colorectal cancer is one of the most common cancers in the United States; second to breast cancer in women and third to prostate and lung cancer in men. Recent predictions indicate that in 1994, 149,000 new cases of colorectal cancer (107,000 colon, 42,000 rectal) will be diagnosed and 56,000 patients will die of their disease. Objective is to determine the response rate of GI147211. To determine the time to progression of disease and To evaluate the safety and tolerability when administered by daily injection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NSABP P-1--TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER
MX 405: INTRADOSE (CISPLATIN & EPINEPHRINE) INJECTABLE GEL
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER
海外基金